Thalidomide Dosing in Patients with Relapsed or Refractory Multiple Myeloma
| Autor: | Jennifer L Thompson, Lea Ann Hansen |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Oncology
medicine.medical_specialty Antineoplastic Agents 030204 cardiovascular system & hematology Pharmacology 030226 pharmacology & pharmacy Bedtime 03 medical and health sciences 0302 clinical medicine Recurrence Internal medicine medicine Humans Pharmacology (medical) In patient Dosing Multiple myeloma Clinical Trials as Topic Dose-Response Relationship Drug business.industry Refractory Multiple Myeloma medicine.disease Thalidomide Clinical trial Search terms Multiple Myeloma business medicine.drug |
| Zdroj: | Annals of Pharmacotherapy. 37:571-576 |
| ISSN: | 1542-6270 1060-0280 |
| DOI: | 10.1345/aph.1a155 |
| Popis: | OBJECTIVE: To evaluate the literature regarding the dosing of thalidomide in multiple myeloma. DATA SOURCES: A MEDLINE search (1990–February 2003) using the search terms thalidomide and multiple myeloma was performed to identify clinical trials and abstracts. Identified literature was then cross-referenced for further pertinent data. DATA SYNTHESIS: Patients with relapsed or refractory multiple myeloma have few therapeutic options. Thalidomide is a promising agent, although many dose-related issues are still in question. Starting doses studied ranged from 50 to 200 mg/d, usually given at bedtime. Gradual dose escalation up to 800 mg/d has been studied, with some evidence of improved outcome with doses of 400–600 mg/d, while thalidomide appears to be best tolerated at doses ≤400 mg/d. CONCLUSIONS: A reasonable approach for use of thalidomide in multiple myeloma is to initiate therapy at 50–100 mg nightly and escalate every 2 weeks in 50-to 100-mg increments as tolerated. Efforts should be made to titrate the dose to 400–600 mg/d, especially in patients with poor prognostic features. Efficacy should be assessed at approximately 8 weeks and the dose maintained if desired response is achieved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|